We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current STPHF market cap is 0. The company's latest EPS is JPY and P/E is N/A.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 0 | 205.97M | 100.1M | 229.07M | 269.49M |
| Operating Income | -951.41M | -680.57M | -741.9M | -806.78M | -760.3M |
| Net Income | -962.24M | -659.24M | -767.72M | -778.82M | -763.75M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 2.66B | 2.05B | 4.72B | 4.33B | 3.82B |
| Total Liabilities | 1.97B | 1.82B | 1.64B | 1.58B | 1.44B |
| Total Equity | 690.03M | 230.72M | 3.08B | 2.75B | 2.38B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | -913.58M | -772.81M | -1.08B | -827.67M | -876.84M |
| Investing | 1.56B | -22.86M | -350.56M | -29.93M | -9.01M |
| Financing | -68.58M | -332.4M | 3.83B | 291.82M | 228.35M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 31.23M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Stella Pharma Corporation (GM) |
| Address |
orix kouraibashi building osaka, osaka 541-0043 |
| Website | https://stella-pharma.co.jp/en |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
